Most widely filed vaccine and medicine for registration where need is highest
Of infectious diseases, pneumonia is the biggest killer: in 2017 it caused 2.56 million deaths globally, almost a third were in children under five. Fungal diseases, largely neglected, affect more than a billion people, and are fatal for more than 1.5 million each year. When companies file products such as vaccines and antifungals for registration, this represents an important step in making them available for sale. The Benchmark has identified 102 low- and middle-income countries where greater access to antibacterial and antifungal medicines are needed, referred to as 'access countries'.
How does Pfizer represent best practice?
Pfizer demonstrates best practice by widely filing its on-patent vaccine Prevnar 13® (which prevents pneumococcal disease, including pneumonia and meningitis) and its off-patent antifungal fluconazole (Diflucan®, which treats diseases caused by Candida spp. and Cryptococcus spp.). Pfizer has filed Prevnar 13® for registration in 62 access countries (11 low-income, 32 lower middle-income and 19 upper middle-income), including six sub-Saharan countries (Angola, Lesotho, Sierra Leone, Sudan, Swaziland and Zimbabwe). On a similar scale, it has filed fluconazole (Diflucan®) for registration in 61 access countries. This level of filing is the highest for all of the 156 products the Benchmark assesses.